Ronald R. Taylor net worth and biography

Ronald Taylor Biography and Net Worth

Director of ResMed

Ron Taylor has served as a ResMed director since January 2005 and its independent lead director since July 1, 2013. He is chair of ResMed’s nominating and governance committee and a member of the audit and compliance oversight committees.

In 1987, Mr. Taylor founded Pyxis Corporation, a manufacturer of automated drug dispensers for hospitals, where he served as chairman, president, and CEO until its purchase by Cardinal Health, Inc., in 1996. For six years before founding Pyxis, Mr. Taylor was responsible for operations and international sales at Hybritech, Inc., a biotechnology company. Before joining Hybritech, he served for 10 years in management roles at Allergan plc (NYSE: AGN), a pharmaceutical company. From 1998-2001, he was a general partner at Enterprise Partners Venture Capital.

Mr. Taylor’s past public company board experience includes serving as a director at Allergan from 1994 through 2018. From 1998 through 2014, he served as a member of the Red Lion Hotels governance, compensation, and audit committees. From 2002 until his appointment to the ResMed board in 2005, he served as chairman of the ResMed Foundation.

Mr. Taylor has a B.A. from the University of Saskatchewan and an M.A. from the University of California, Irvine.

What is Ronald R. Taylor's net worth?: The estimated net worth of Ronald R. Taylor is at least $4.54 million as of February 19th, 2021. Mr. Taylor owns 18,769 shares of ResMed stock worth more than $4,540,221 as of November 21st. This net worth estimate does not reflect any other assets that Mr. Taylor may own. Learn More about Ronald R. Taylor's net worth.
How do I contact Ronald R. Taylor?: The corporate mailing address for Mr. Taylor and other ResMed executives is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. ResMed can also be reached via phone at (858) 836-5000 and via email at [email protected]. Learn More on Ronald R. Taylor's contact information.
Has Ronald R. Taylor been buying or selling shares of ResMed?: Ronald R. Taylor has not been actively trading shares of ResMed over the course of the past ninety days. Most recently, Ronald R. Taylor sold 4,000 shares of the business's stock in a transaction on Friday, February 19th. The shares were sold at an average price of $200.14, for a transaction totalling $800,560.00. Following the completion of the sale, the director now directly owns 18,769 shares of the company's stock, valued at $3,756,427.66. Learn More on Ronald R. Taylor's trading history.
Who are ResMed's active insiders?: ResMed's insider roster includes Carol Burt (Director), Jan De Witte (Director), Robert Douglas (COO), Karen Drexler (Director), Michael Farrell (CEO), Peter Farrell (Director), Kaushik Ghoshal (Insider), James Hollingshead (Insider), Justin Leong (Insider), David Pendarvis (Insider), Michael Rider (General Counsel), Brett Sandercock (CFO), Rajwant Sodhi (Insider), and Ronald Taylor (Director). Learn More on ResMed's active insiders.
Are insiders buying or selling shares of ResMed?: In the last twelve months, insiders at the medical equipment provider sold shares 27 times. They sold a total of 187,789 shares worth more than $41,061,987.20. The most recent insider tranaction occured on November, 12th when Director Witte Jan De sold 796 shares worth more than $198,052.76. Insiders at ResMed own 0.7% of the company. Learn More about insider trades at ResMed.
Information on this page was last updated on 11/12/2024.

Ronald R. Taylor Insider Trading History at ResMed

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/19/2021	Sell	4,000	$200.14	$800,560.00	18,769
8/20/2019	Sell	4,429	$136.34	$603,849.86	19,855
1/24/2018	Sell	4,885	$99.71	$487,083.35	21,751
8/17/2016	Buy	2,487	$69.13	$171,926.31	16,729
8/16/2016	Sell	23,102	$69.25	$1,599,813.50	16,729

Ronald R. Taylor Buying and Selling Activity at ResMed

ResMed Company Overview

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Today's Range

Now: $241.90

$240.68

$242.75

50 Day Range

MA: $242.10

$231.43

$256.07

2 Week Range

Now: $241.90

$151.95

$260.49

Volume

125,983 shs

Average Volume

1,039,828 shs

Market Capitalization

$35.51 billion

P/E Ratio

32.04

Dividend Yield

0.89%

Beta

0.69

Urgent: This election is rigged

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.